Alzheimer's Disease

Origent has recently expanded its capabilities for Alzheimer’s disease modeling.  Our most advanced AD predictive models leverage dozens of variables related to each patient and simulate personalized progression outcomes up to 24 months in the future.  With your additional clinical data, these models can be expanded further.

Origent has focused its modeling efforts on predicting the most common clinical trial endpoints.  These include the ADAS-cog score and ADCS/ADL.  Additional models targeted and predicting progression of individual symptoms are under development.

How does Origent help reduce risk in Alzheimer's disease clinical trials?

Learn About Applications

Pin It on Pinterest

Share This